ClinicalTrials.gg
Not yet recruitingNCT07922694Updated Nov 6, 2026

Obesity-Related Indices and Albuminuria in Type 2 Diabetes

An observational study in Obesity and Diabetes Mellitus, Type 2 and Albuminuria, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Assiut University · Observational

Updated Nov 6, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
349
Ages
18 Years and older
Sex
All
01

Study summary

This cross-sectional study aims to evaluate obesity-related indices and albuminuria levels in patients with type 2 diabetes mellitus.

Read the detailed description

Type 2 diabetes mellitus is a leading cause of chronic kidney disease. Obesity-related indices such as body mass index, waist-to-height ratio, body roundness index, visceral adiposity index, and triglyceride-glucose index are simple measures of body composition and metabolic status.

This observational study will calculate multiple obesity-related indices and measure urine albumin-to-creatinine ratio in adult patients with type 2 diabetes mellitus.

02

Conditions studied

  • Obesity and Diabetes Mellitus, Type 2
  • Albuminuria

Keywords

  • Type 2 diabetes
  • Obesity indices
  • Albuminuria
  • Body mass index
  • Assiut
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 349 is above the median of 114 across 2,154 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients aged 18 years or older with established type 2 diabetes mellitus attending Assiut University Hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Age 18 years or older
  • Established diagnosis of type 2 diabetes mellitus
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • - Type 1 diabetes mellitus
  • Pregnancy
  • Acute kidney injury
  • Known primary glomerular disease
  • Active urinary tract infection
  • Decompensated liver disease or active
  • Advanced chronic kidney disease ( \<60 mL/min/1.73m²)
  • Conditions preventing reliable anthropometric assessment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
349 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Type 2 Diabetes Mellitus

    Adult patients with established type 2 diabetes mellitus who will undergo anthropometric measurements and laboratory assessment of albuminuria.

06

What researchers measure

Primary outcomes

  1. Urine albumin-to-creatinine ratio

    Mean urine albumin-to-creatinine ratio in milligrams per gram.

    Time frame: Baseline

Secondary outcomes

  1. Body mass index

    Mean body mass index calculated as weight in kilograms divided by height in meters squared.

    Time frame: Baseline

  2. Waist-to-height ratio

    Mean waist-to-height ratio calculated as waist circumference divided by height.

    Time frame: Baseline

  3. Body roundness index

    Mean body roundness index calculated from waist circumference and height.

    Time frame: Baseline

  4. Estimated glomerular filtration rate

    Mean estimated glomerular filtration rate calculated by the CKD-EPI 2021 equation in milliliters per minute per 1.73 square meters.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07922694
Lead sponsor
Assiut University
Responsible party
Mahmoud Marouf Sadek (Resident Physician, Department of Internal Medicine, Assiut University) — Principal investigator
First posted
Nov 6, 2026
Start date
Nov 10, 2026 (estimated)
Primary completion
Nov 10, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Mahmoud M Sadek, Resident
Contact
Mahmud.18313212@med.aun.edu.eg
01550428880
Manal E EzzEl-dine Abdel-Mooty, prof
study chair · Internal Medicine Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion